11C-MET PET(/CT) vs 18F-FDG PET(/CT) in the follow-up of differentiated thyroid cancer*

11C-MET PET(/CT) vs 18F-FDG PET(/CT) in the follow-up of differentiated thyroid cancer* - 11C-MET PET(/CT) in DTC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32909

Enrollment

Registered

2009-01-14

Start date

2019-07-22

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

differentiated thyroid carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Study 1 - > 18 years old - Total thyroidectomy - Negative post-treatment 131I-WBS with elevated Tg(on) (>5.0 ng/ml) - Signed informed consent ;Study 2 - > 18 years old - Total thyroidectomy - Patients with persistent or recurrent Hürthlecell carcinoma in post-ablation phase or during follow-up - Signed informed consent

Exclusion criteria

Exclusion criteria: Both studies: - Pregnancy - Patients with any signs of neurological or psychiatric disorders that will preclude him/her from expressing her/his own free will

Design outcomes

Primary

Measure	Time frame
A qualitative and semi-quantitative (standardized uptake values (SUVs)) reading of all the PET studies will be performed. Comparison with data derived from clinical CT imaging data, and where feasible histological or cytological confirmation, will take place. Ojective/Study 1: the results of 11C-MET PET will be compared with the clinical FDG PET Objective/Study 2: the results of 11C-MET PET will be compared with the clinical FDG PET The results of both PET scan will also be compared with the (diagnostic and) post-treatment 131I-WBS.	—

Measure

Time frame

A qualitative and semi-quantitative (standardized uptake values (SUVs)) reading of all the PET studies will be performed. Comparison with data derived from clinical CT imaging data, and where feasible histological or cytological confirmation, will take place. Ojective/Study 1: the results of 11C-MET PET will be compared with the clinical FDG PET Objective/Study 2: the results of 11C-MET PET will be compared with the clinical FDG PET The results of both PET scan will also be compared with the (diagnostic and) post-treatment 131I-WBS.

—

Secondary

Measure	Time frame
Premature termination of the study will be only if interim analysis after 15 and 10 evaluable scans for study/objective 1 and study/objective 2, respectively, showed negative or undoubtedly results for the 11C-MET PET compared to the clinical FDG PET.	—

Countries

Netherlands

Outcome results